Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Xiaohong Wang


Annals of Oncology (2019) 30 (suppl_5): v591-v601. 10.1093/annonc/mdz259


X. Wang1, Y. Liu2, Z. Meng2, Y. Wu3, S. Wang3, G. Jin4, Y. Qin4, F. Wang5, J. Wang5, L. Wang6, J. Bai7, X. Shi8, Z. Wen9, X. Jia9, X. Fu10, X. Wang11, Q. Qin12, Y. Gao12, W. Guo13, S. Lu14

Author affiliations

  • 1 Chest Oncology Medicine, Baotou Cancer Hospital, 14000 - Baotou/CN
  • 2 Chest Oncology Medicine, Baotou Cancer Hospital, Baotou/CN
  • 3 Department Of Oncology, Baotao Central Hospital, Baotou/CN
  • 4 Medical Oncology Division2, Inner Mongolia Autonomous Region People's Hospital, Hohhot/CN
  • 5 Department Of Oncology, The Affiliated Third Hospital of Baotou Medical College, Baotou/CN
  • 6 Bioinformatics, BerryOncology Corporation, Beijing/CN
  • 7 Bioinformatics, BerryOncology Corporation, 100101 - Beijing/CN
  • 8 Department Of Oncology, Bayan Nur Hospital, Bayan Nur/CN
  • 9 Department Of Oncology, Inner Mongolia Cancer Hospital, Hohhot/CN
  • 10 Department Of Respiratory Medicine, Affiliated Hospital of Inner Mongolia Medical University, Hohhot/CN
  • 11 Department Of Oncology Medicine, Affiliated Hospital of Inner Mongolia Medical University, Hohhot/CN
  • 12 Department Of Oncology, People's Hospital of Da La Te Banner, Inner Mongolia Autonomous Region, Da La Te Banner/CN
  • 13 Department Of Oncology, Ⅰnner Mongolia Baogang Hospital, Baotou/CN
  • 14 Medical Oncology, Shanghai Chest Hospital, 200030 - Shanghai/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3663


Although liquid biopsy has been reported in detecting actionable mutations, and is becoming standard of care in non-small cell lung cancer (NSCLC) under certain circumstances, the relationship between plasma mutant allele fractions (MAFs) and treatment responsiveness remains unclear.


This study enrolled 134 patients with advanced NSCLC. Tumor tissue specimens were collected after surgery, and peripheral blood samples were collected at baseline (before surgery) and during treatments. Amplification-refractory mutation system (ARMS) was performed for EGFR mutation screening in all tumor tissues. Circulating single-molecule amplification and resequencing technology (cSMART) was performed in all cfDNA samples using a panel of nine genes including EGFR. EGFR status were compared between tumor tissue and matched cfDNA samples. Moreover, the association between MAFs of EGFR mutations in cfDNA and the responsiveness to tyrosine-kinase inhibitor (TKI) treatment was analyzed.


EGFR mutations were detected in 56 tumor samples (56/134, ∼41.8%) and 67 matched baseline plasma cfDNA samples (67/134, 50.0%), the concordance rate between tumor and cfDNA samples is 82.8%. Specifically, EGFR exon19 non-frameshift deletions were detected in 24 tumor tissue and 23 matched cfDNA samples (concordance rate 97.8%), EGFR p.L858R mutations were detected in 24 tumor tissue and 22 matched cfDNA samples (concordance rate 97.0%). The overall response rate (ORR) and disease control rate (DCR) for EGFR mutation positive patients (TKI sensitive mutations only) were 47.6% and 73.8%, respectively. More importantly, for TKI-treated patients with original plasma EGFR MAFs higher than 0.1% and lower than 0.1%, the ORRs were 58.6% and 23.1% (17/29 versus 3/13 patients, P = 0.047), respectively.


In this study we confirmed that liquid biopsy based screening is reliable for actionable somatic mutation detection. The plasma mutant allele fraction of EGFR driver mutation tend to associate with the responsiveness to TKI targeted treatment. Larger cohorts are needed to clarify the impact of plasma MAFs in predicting treatment responsiveness.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.